A major new study has raised an urgent warning for people with type 2 diabetes: stopping a popular class of medications, known as GLP-1 agonists, could nearly double the risk of suffering a heart attack or stroke.
A Landmark, Concerning Finding
A new large-scale study published in The
Lancet Regional Health - Europe has uncovered a significant risk associated with discontinuing certain diabetes medications. Researchers analysed the health records of over 80,000 people with type 2 diabetes in Italy and found a startling connection. Patients who stopped taking GLP-1 receptor agonists had approximately twice the risk of a non-fatal heart attack, non-fatal stroke, or death from any cause compared to those who continued their treatment. This translates to about four major cardiovascular events per 100 people each year among those who stopped, versus two events for those who remained on the medication. The study highlights that the protective benefits of these drugs may be lost quickly upon discontinuation, underscoring the importance of viewing them as long-term treatments, not short-term fixes.
Understanding These Powerful Medications
The drugs in question are GLP-1 receptor agonists, a class of medications that includes well-known drugs like semaglutide and liraglutide. Originally developed to help manage blood sugar in people with type 2 diabetes, they work by mimicking a natural hormone that regulates insulin and appetite. This mechanism not only helps control blood sugar but also often leads to significant weight loss and provides known benefits for heart and kidney health. Their effectiveness has made them a cornerstone in modern diabetes and obesity management. However, the new findings suggest their powerful cardiovascular shield is only active when the medication is consistently taken. The protective effect is not a permanent change but a continuous benefit of being on the treatment.
Why Do Patients Stop Taking Them?
Despite their proven benefits, a substantial number of patients discontinue these medications, often within the first year. The Italian study noted that over 60% of patients had stopped their treatment. The reasons are complex and varied. Common factors include challenging side effects like nausea and other gastrointestinal issues, which can be difficult for some to tolerate. The high cost of the drugs and issues with insurance coverage or supply shortages are also significant barriers for many. Furthermore, some patients may stop after reaching their weight loss goals, mistakenly believing the medication is no longer needed. The study's authors noted that since their research was observational, they could not definitively know why each person stopped, which could also include factors like worsening overall health.
The Importance of Continuous Medical Guidance
The key takeaway from this research is not that the drugs are dangerous, but that they are most effective when used consistently under a doctor's supervision. Experts stress that diabetes is a chronic disease requiring long term management. Stopping a medication like a GLP‑1 agonist is not like finishing a course of antibiotics; the underlying condition and its associated risks return once the drug's effects wear off. This can lead to a rebound in appetite, weight regain, and, as the study shows, a loss of crucial cardiovascular protection. The researchers found that even after stopping, patients' weight, blood sugar, and blood pressure only changed modestly, suggesting these factors alone don't explain the large jump in risk. This points to a more direct protective effect of the drug that is lost upon discontinuation.
